The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial

• Published in: Scientific reports Vol. 8; no. 1; pp. 2964 - 11
• Main Authors: Sun, Yi-Yuan, Li, Ming, Li, Yue-Yue, Li, Li-Xiang, Zhai, Wen-Zhe, Wang, Peng, Yang, Xiao-Xiao, Gu, Xiang, Song, Li-Jin, Li, Zhen, Zuo, Xiu-Li, Li, Yan-Qing
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 14.02.2018; Nature Publishing Group
• Subjects: 45/43; 45/91; 631/208/514; 692/4020/1503/1502/2071; Clostridium butyricum; Diarrhea; Double-blind studies; Fecal microflora; Feces; Gastrointestinal diseases; Humanities and Social Sciences; Intestine; Irritable bowel syndrome; Microbiota; multidisciplinary; Probiotics; Quality of life; Science; Science (multidisciplinary)

Irritable bowel syndrome (IBS) is a common disorder in gastrointestinal system and impairs the quality of life of the patients. Clostridium butyricum ( CB ) is a probiotics that has been used in several gastrointestinal diseases. The efficacy of CB in treating IBS is still unknown. This prospective,...